Barclays raises Regeneron Pharmaceuticals (NASDAQ:REGN) price target from $888 to $900

By / / Barclays, Regeneron Pharmaceuticals

Barclays analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $888 to $900.

Scroll to Top